Arroyo Grande AI company expands ops
Kinomatic is expanding operations beyond the Central Coast after the company announced it would be opening its new office in Cleveland’s Health-Tech Corridor on Sept. 15. The Arroyo Grande-based company, which specializes in AI- and VR-driven orthopedic surgery planning and concierge recovery, announced that this is its first expansion beyond California and a deliberate step Read More →
Tri-county companies make key additions
• Santa Barbara-based Bitwarden announced the appointment of Mary Writz as chief product officer. Writz brings more than 20 years of cybersecurity and product leadership experience and will lead product strategy and portfolio development for the company, which serves more than 15 million users and over 80,000 businesses across 180 countries. • Westlake Village-based Turn Therapeutics, Read More →
AeroVironment piles on wins with latest earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Kite Pharma relocating to Thousand Oaks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Kite Pharma relocating to Thousand Oaks
Santa Monica-headquartered Kite Pharma is relocating its home office to two locations in Thousand Oaks and El Segundo. The company, which specializes in engineered cell therapy to treat and cure cancer, says in a LinkedIn post that the move will be made at the end of 2026. Kite will be the latest addition to the Read More →
Latigo reports first earnings since going public, highlights successful IPO
In its first earnings report since going public, Latigo Biotherapeutics highlighted the success of its upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million. Based in Thousand Oaks, Latigo Biotherapeutics is a pre-revenue, clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines. Read More →
